| Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates |
- Duchenne (SGT-003) : Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 - - FA (SGT-212): Dosing of first participant anticipated in the second half of 2025 - - CPVT (SGT-501): FDA IND on track for submission first half of 2025 - - Cash: Company ended first quarter 2025 with $306.9 million in cash, cash equivalents, investments and available-for-sale securities; Solid has anticipated cash runway into the first half of 2027 - CHARLESTOWN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision, next generation, genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-15 20:06:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees. |
globenewswire.com |
2025-05-01 20:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Participate at The Citizens Life Sciences Conference |
CHARLESTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, at 12:30 pm ET. |
globenewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting |
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), from May 13-17, 2025, in New Orleans, LA. |
globenewswire.com |
2025-04-29 12:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space |
Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich's ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. |
seekingalpha.com |
2025-04-08 20:50:08 |
Czytaj oryginał (ang.) |
| Can Solid Biosciences Challenge Sarepta in the DMD Market? |
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. |
marketbeat.com |
2025-04-08 11:31:50 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees. |
globenewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul |
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies. |
nypost.com |
2025-03-31 18:25:42 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference |
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025. |
globenewswire.com |
2025-03-12 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-03-07 12:55:33 |
Czytaj oryginał (ang.) |
| SLDB Stock Rallies 60% in a Month: Here's What You Should Know |
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003. |
zacks.com |
2025-03-07 12:16:14 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates |
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways - |
globenewswire.com |
2025-03-06 18:16:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Participate at Upcoming Investor Conferences |
CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: |
globenewswire.com |
2025-03-05 10:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,950 restricted stock units (“RSUs”) to one newly hired employee. |
globenewswire.com |
2025-03-04 18:07:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? |
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. |
marketbeat.com |
2025-02-19 10:48:09 |
Czytaj oryginał (ang.) |
| Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data |
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy. |
benzinga.com |
2025-02-18 14:29:22 |
Czytaj oryginał (ang.) |
| Solid Biosciences Announces Pricing of Underwritten Offering |
CHARLESTOWN, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the pricing of an underwritten offering of 35,739,810 shares of its common stock at an offering price of $4.03 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 13,888,340 shares of common stock at an offering price of $4.029 per pre-funded warrant. The aggregate gross proceeds of the offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. All of the securities in the offering are being sold by Solid. The offering is expected to close on or about February 19, 2025, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2025-02-18 09:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 |
— Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% (N=3) and significant improvements in multiple additional muscle health biomarkers observed support the potential of SGT-003 as a next-generation, best-in-class Duchenne muscular dystrophy gene therapy candidate —— Encouraging early signals of potential cardiac benefit observed ——SGT-003 has been well-tolerated in the 6 participants dosed as of February 11, 2025, with no serious adverse events observed —— Participant enrollment continues, with the 7th participant dosed on February 17, 2025; Company expects to dose approximately 20 total participants by Q4 2025 —— In mid-2025, Company plans to request an FDA meeting to discuss potential accelerated approval pathway for SGT-003 —— Company to hold a conference call today at 8:00 AM ET — |
globenewswire.com |
2025-02-18 08:45:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart |
Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025. |
seekingalpha.com |
2025-01-21 20:27:23 |
Czytaj oryginał (ang.) |
| Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia |
- Only dual route gene transfer therapy in development to treat Friedreich's ataxia with FDA IND clearance and Fast Track designation - |
globenewswire.com |
2025-01-21 10:30:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines |
- Duchenne : Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - |
globenewswire.com |
2025-01-15 18:05:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). |
globenewswire.com |
2025-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia |
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia. |
zacks.com |
2025-01-08 13:26:09 |
Czytaj oryginał (ang.) |
| Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia |
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - |
globenewswire.com |
2025-01-07 18:15:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Added to the Nasdaq Biotechnology Index |
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. |
globenewswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst |
Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD). |
benzinga.com |
2024-12-13 15:52:38 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Participate at Upcoming Investor Conferences |
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: |
globenewswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Present at the Jefferies London Healthcare Conference |
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET). |
globenewswire.com |
2024-11-14 10:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates |
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - |
globenewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired employees. |
globenewswire.com |
2024-10-02 20:15:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference |
CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 am ET. |
globenewswire.com |
2024-09-12 12:00:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired employees. |
globenewswire.com |
2024-09-04 20:05:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates |
– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 – |
globenewswire.com |
2024-08-13 20:08:00 |
Czytaj oryginał (ang.) |
| Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired employee. |
globenewswire.com |
2024-07-01 20:19:00 |
Czytaj oryginał (ang.) |